Breaking Finance News

Nuvectra Corp (NASDAQ:NVTR) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Nuvectra Corp (NASDAQ:NVTR) to Hold in a statement released on Wednesday January 11, 2017.

On 11/16/2016, Zacks Investment Research released a statement about Nuvectra Corp (NASDAQ:NVTR) upped the target price from $0.00 to $5.50 that suggested an upside of 0.11%.

Having a price of $5.86, Nuvectra Corp (NASDAQ:NVTR) traded 7.54% higher on the day. With the last stock price down -7.06% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.04% over the date range. Nuvectra Corp has recorded a 50-day average of $5.51 and a two hundred day average of $6.29. Volume of trade was down over the average, with 0 shares of NVTR changing hands under the typical 46,813

Performance Chart

Nuvectra Corp (NASDAQ:NVTR)

With a total market value of $0, Nuvectra Corp has with a one year low of $4.02 and a one year high of $11.64 .

A total of 2 analysts have released a research note on NVTR. zero analysts rating the company a strong buy, 0 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $13.00.

About Nuvectra Corp (NASDAQ:NVTR)

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.